Related Experiment Videos
[Primary pulmonary hypertension and its management]
C Crespo Martínez1, V Morales León, H Alonso Ramos
1Servicio de Farmacia, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria.
Summary
Primary pulmonary hypertension (PPH) treatment has advanced beyond vasodilators to address vascular remodeling and thrombosis. New therapies improve outcomes, reducing the need for pulmonary transplants.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Context:
- Primary pulmonary hypertension (PPH) is a severe condition with elevated pulmonary arterial pressure.
- Traditional treatment focused on calcium channel blockers for vasodilation.
Purpose:
- To review current therapeutic strategies for PPH.
- To highlight advancements beyond traditional vasodilator therapy.
Summary:
- Current PPH treatments target vasoconstriction, vascular remodeling, and thrombosis.
- Therapies include prostacyclin analogs, endothelin-receptor antagonists, and nitric oxide pathway modulators.
Impact:
- These pharmacological advances have decreased the reliance on pulmonary transplantation.
- Improved treatment options offer better management for PPH patients.